Oncology
HR+ HER2- Breast Cancer
Conference Reporter in HR+ HER2- Breast Cancer to Cover Key Topics Being Presented at the 2024 ASCO Annual Meeting
Overview
Conference Reporter delivers health care providers with insights from key thought leaders on exciting news presented at major medical conferences, in a concise and timely format. Conference Reporter will feature community-selected experts and topics in HR+ HER2- Breast Cancer presented at this year’s ASCO Meeting.
VIEW THE TOPICS
- Advances in the Treatment of HR2+/HER2- Breast Cancer
- HR+/HER2- Breast Cancer and the Problem of Resistance to Endocrine Therapies
- Identifying Candidates for Neoadjuvant or Adjuvant Anti-Her2 Therapy
- Importance of Next-Generation Sequencing in Guiding Therapy Selection
- Second-line Treatment for Advanced/Metastatic HR+/HER2- Breast Cancer
- The Role of Predictive Biomarkers for Patients With HR+ Breast Cancer
This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American Society of Clinical Oncology.